- call +1-201-465-4211
- email sales@mrinsights.biz
The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
Scope of the Report:
The research usually can last 8-10 years, so scale production will occur in 2018. Before then, the Human Micobiome companies have to continue deficit.
At present, global investment concentrates in US and Europe, US takes 70% market share and Europe takes 25% market share. There are a few manufacturers in the world and the market concentration is high. The top5 (investment in Human Micobiome) companies are Vedanta, Seres Therapeutics, Second Genome, Rebiocix, ActoGeniX. The five companies occupy about 70% of the market share.
The global Human Micobiome market is valued at 170 million USD in 2018 and is expected to reach 610 million USD by the end of 2024, growing at a CAGR of 23.9% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Human Micobiome.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Human Micobiome market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Human Micobiome market by product type and applications/end industries.
Market Segment by Companies, this report covers
Vedanta
Seres Therapeutics
Second Genome
Rebiotix
ActoGeniX
Enterome BioScience
AvidBiotics
4D Pharma Research Ltd
Enterologics
Metabogen
Metabiomics
Ritter Pharmaceuticals
Osel
Symberix
Miomics
Symbiotix Biotherapies
MicroBiome Therapeutics LLC
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Gastrointestinal Tract Human Micobiome
Urogenital Tract Human Micobiome
Other
Market Segment by Applications, can be divided into
Treatment
Diagnosis
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Human Micobiome Market Overview
1.1 Product Overview and Scope of Human Micobiome
1.2 Classification of Human Micobiome by Types
1.2.1 Global Human Micobiome Revenue Comparison by Types (2019-2024)
1.2.2 Global Human Micobiome Revenue Market Share by Types in 2018
1.2.3 Gastrointestinal Tract Human Micobiome
1.2.4 Urogenital Tract Human Micobiome
1.2.5 Other
1.3 Global Human Micobiome Market by Application
1.3.1 Global Human Micobiome Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 Treatment
1.3.3 Diagnosis
1.4 Global Human Micobiome Market by Regions
1.4.1 Global Human Micobiome Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) Human Micobiome Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Human Micobiome Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Human Micobiome Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) Human Micobiome Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Human Micobiome Status and Prospect (2014-2024)
1.5 Global Market Size of Human Micobiome (2014-2024)
2 Manufacturers Profiles
2.1 Vedanta
2.1.1 Business Overview
2.1.2 Human Micobiome Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Vedanta Human Micobiome Revenue, Gross Margin and Market Share (2017-2018)
2.2 Seres Therapeutics
2.2.1 Business Overview
2.2.2 Human Micobiome Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Seres Therapeutics Human Micobiome Revenue, Gross Margin and Market Share (2017-2018)
2.3 Second Genome
2.3.1 Business Overview
2.3.2 Human Micobiome Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Second Genome Human Micobiome Revenue, Gross Margin and Market Share (2017-2018)
2.4 Rebiotix
2.4.1 Business Overview
2.4.2 Human Micobiome Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Rebiotix Human Micobiome Revenue, Gross Margin and Market Share (2017-2018)
2.5 ActoGeniX
2.5.1 Business Overview
2.5.2 Human Micobiome Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 ActoGeniX Human Micobiome Revenue, Gross Margin and Market Share (2017-2018)
2.6 Enterome BioScience
2.6.1 Business Overview
2.6.2 Human Micobiome Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Enterome BioScience Human Micobiome Revenue, Gross Margin and Market Share (2017-2018)
2.7 AvidBiotics
2.7.1 Business Overview
2.7.2 Human Micobiome Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 AvidBiotics Human Micobiome Revenue, Gross Margin and Market Share (2017-2018)
2.8 4D Pharma Research Ltd
2.8.1 Business Overview
2.8.2 Human Micobiome Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 4D Pharma Research Ltd Human Micobiome Revenue, Gross Margin and Market Share (2017-2018)
2.9 Enterologics
2.9.1 Business Overview
2.9.2 Human Micobiome Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Enterologics Human Micobiome Revenue, Gross Margin and Market Share (2017-2018)
2.10 Metabogen
2.10.1 Business Overview
2.10.2 Human Micobiome Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Metabogen Human Micobiome Revenue, Gross Margin and Market Share (2017-2018)
2.11 Metabiomics
2.11.1 Business Overview
2.11.2 Human Micobiome Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Metabiomics Human Micobiome Revenue, Gross Margin and Market Share (2017-2018)
2.12 Ritter Pharmaceuticals
2.12.1 Business Overview
2.12.2 Human Micobiome Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Ritter Pharmaceuticals Human Micobiome Revenue, Gross Margin and Market Share (2017-2018)
2.13 Osel
2.13.1 Business Overview
2.13.2 Human Micobiome Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Osel Human Micobiome Revenue, Gross Margin and Market Share (2017-2018)
2.14 Symberix
2.14.1 Business Overview
2.14.2 Human Micobiome Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Symberix Human Micobiome Revenue, Gross Margin and Market Share (2017-2018)
2.15 Miomics
2.15.1 Business Overview
2.15.2 Human Micobiome Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Miomics Human Micobiome Revenue, Gross Margin and Market Share (2017-2018)
2.16 Symbiotix Biotherapies
2.16.1 Business Overview
2.16.2 Human Micobiome Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Symbiotix Biotherapies Human Micobiome Revenue, Gross Margin and Market Share (2017-2018)
2.17 MicroBiome Therapeutics LLC
2.17.1 Business Overview
2.17.2 Human Micobiome Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 MicroBiome Therapeutics LLC Human Micobiome Revenue, Gross Margin and Market Share (2017-2018)
3 Global Human Micobiome Market Competition, by Players
3.1 Global Human Micobiome Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Human Micobiome Players Market Share
3.2.2 Top 10 Human Micobiome Players Market Share
3.3 Market Competition Trend
4 Global Human Micobiome Market Size by Regions
4.1 Global Human Micobiome Revenue and Market Share by Regions
4.2 North America Human Micobiome Revenue and Growth Rate (2014-2019)
4.3 Europe Human Micobiome Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific Human Micobiome Revenue and Growth Rate (2014-2019)
4.5 South America Human Micobiome Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa Human Micobiome Revenue and Growth Rate (2014-2019)
5 North America Human Micobiome Revenue by Countries
5.1 North America Human Micobiome Revenue by Countries (2014-2019)
5.2 USA Human Micobiome Revenue and Growth Rate (2014-2019)
5.3 Canada Human Micobiome Revenue and Growth Rate (2014-2019)
5.4 Mexico Human Micobiome Revenue and Growth Rate (2014-2019)
6 Europe Human Micobiome Revenue by Countries
6.1 Europe Human Micobiome Revenue by Countries (2014-2019)
6.2 Germany Human Micobiome Revenue and Growth Rate (2014-2019)
6.3 UK Human Micobiome Revenue and Growth Rate (2014-2019)
6.4 France Human Micobiome Revenue and Growth Rate (2014-2019)
6.5 Russia Human Micobiome Revenue and Growth Rate (2014-2019)
6.6 Italy Human Micobiome Revenue and Growth Rate (2014-2019)
7 Asia-Pacific Human Micobiome Revenue by Countries
7.1 Asia-Pacific Human Micobiome Revenue by Countries (2014-2019)
7.2 China Human Micobiome Revenue and Growth Rate (2014-2019)
7.3 Japan Human Micobiome Revenue and Growth Rate (2014-2019)
7.4 Korea Human Micobiome Revenue and Growth Rate (2014-2019)
7.5 India Human Micobiome Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia Human Micobiome Revenue and Growth Rate (2014-2019)
8 South America Human Micobiome Revenue by Countries
8.1 South America Human Micobiome Revenue by Countries (2014-2019)
8.2 Brazil Human Micobiome Revenue and Growth Rate (2014-2019)
8.3 Argentina Human Micobiome Revenue and Growth Rate (2014-2019)
8.4 Colombia Human Micobiome Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue Human Micobiome by Countries
9.1 Middle East and Africa Human Micobiome Revenue by Countries (2014-2019)
9.2 Saudi Arabia Human Micobiome Revenue and Growth Rate (2014-2019)
9.3 UAE Human Micobiome Revenue and Growth Rate (2014-2019)
9.4 Egypt Human Micobiome Revenue and Growth Rate (2014-2019)
9.5 Nigeria Human Micobiome Revenue and Growth Rate (2014-2019)
9.6 South Africa Human Micobiome Revenue and Growth Rate (2014-2019)
10 Global Human Micobiome Market Segment by Type
10.1 Global Human Micobiome Revenue and Market Share by Type (2014-2019)
10.2 Global Human Micobiome Market Forecast by Type (2019-2024)
10.3 Gastrointestinal Tract Human Micobiome Revenue Growth Rate (2014-2024)
10.4 Urogenital Tract Human Micobiome Revenue Growth Rate (2014-2024)
10.5 Other Revenue Growth Rate (2014-2024)
11 Global Human Micobiome Market Segment by Application
11.1 Global Human Micobiome Revenue Market Share by Application (2014-2019)
11.2 Human Micobiome Market Forecast by Application (2019-2024)
11.3 Treatment Revenue Growth (2014-2019)
11.4 Diagnosis Revenue Growth (2014-2019)
12 Global Human Micobiome Market Size Forecast (2019-2024)
12.1 Global Human Micobiome Market Size Forecast (2019-2024)
12.2 Global Human Micobiome Market Forecast by Regions (2019-2024)
12.3 North America Human Micobiome Revenue Market Forecast (2019-2024)
12.4 Europe Human Micobiome Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific Human Micobiome Revenue Market Forecast (2019-2024)
12.6 South America Human Micobiome Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa Human Micobiome Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Human Micobiome Picture
Table Product Specifications of Human Micobiome
Table Global Human Micobiome and Revenue (Million USD) Market Split by Product Type
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
